571 related articles for article (PubMed ID: 27984714)
21. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies.
Georgakopoulos JR; Phung M; Ighani A; Yeung J
J Am Acad Dermatol; 2018 Jul; 79(1):155-157. PubMed ID: 29307635
[No Abstract] [Full Text] [Related]
22. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
Tausend W; Downing C; Tyring S
J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic implications of IL-17A blockade in psoriasis.
Puig L; Carrascosa JM
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():1-5. PubMed ID: 25398486
[No Abstract] [Full Text] [Related]
24. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
Blegvad C; Skov L; Zachariae C
Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
[No Abstract] [Full Text] [Related]
25. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
Sherman S; Solomon Cohen E; Amitay-Laish I; Hodak E; Pavlovsky L
Acta Derm Venereol; 2019 Jul; 99(9):769-773. PubMed ID: 31017250
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-17 and innate immunity in infections and chronic inflammation.
Isailovic N; Daigo K; Mantovani A; Selmi C
J Autoimmun; 2015 Jun; 60():1-11. PubMed ID: 25998834
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases.
Fragoulis GE; Siebert S; McInnes IB
Annu Rev Med; 2016; 67():337-53. PubMed ID: 26565676
[TBL] [Abstract][Full Text] [Related]
29. Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis.
Azevedo A; Torres T
Actas Dermosifiliogr; 2017 May; 108(4):305-314. PubMed ID: 27887675
[TBL] [Abstract][Full Text] [Related]
30. A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies.
Campa M; Menter A
Expert Opin Investig Drugs; 2016 Nov; 25(11):1337-1344. PubMed ID: 27687859
[TBL] [Abstract][Full Text] [Related]
31. Anti-IL-17 Agents for Psoriasis: A Review of Phase III Data.
Farahnik B; Beroukhim K; Nakamura M; Abrouk M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J
J Drugs Dermatol; 2016 Mar; 15(3):311-6. PubMed ID: 26954316
[TBL] [Abstract][Full Text] [Related]
32. Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study.
Georgakopoulos JR; Phung M; Ighani A; Lam K; Yeung J
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):e7-e8. PubMed ID: 29846974
[No Abstract] [Full Text] [Related]
33. Ixekizumab (Taltz)--a second IL-17A inhibitor for psoriasis.
Med Lett Drugs Ther; 2016 May; 58(1494):59-60. PubMed ID: 27148922
[No Abstract] [Full Text] [Related]
34. IL-17 targeted therapies for psoriasis.
Chiricozzi A; Krueger JG
Expert Opin Investig Drugs; 2013 Aug; 22(8):993-1005. PubMed ID: 23731078
[TBL] [Abstract][Full Text] [Related]
35. β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.
Kolbinger F; Loesche C; Valentin MA; Jiang X; Cheng Y; Jarvis P; Peters T; Calonder C; Bruin G; Polus F; Aigner B; Lee DM; Bodenlenz M; Sinner F; Pieber TR; Patel DD
J Allergy Clin Immunol; 2017 Mar; 139(3):923-932.e8. PubMed ID: 27502297
[TBL] [Abstract][Full Text] [Related]
36. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.
Reis J; Vender R; Torres T
BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372
[TBL] [Abstract][Full Text] [Related]
37. Secukinumab: IL-17A inhibition to treat psoriatic arthritis.
Speeckaert R; van Geel N; Lambert J; Claeys L; Delanghe JR; Speeckaert MM
Drugs Today (Barc); 2016 Nov; 52(11):607-616. PubMed ID: 28112279
[TBL] [Abstract][Full Text] [Related]
38. Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions.
Wu KK; Lee MP; Lee EB; Wu JJ
J Dermatolog Treat; 2020 Jun; 31(4):359-365. PubMed ID: 30900514
[No Abstract] [Full Text] [Related]
39. Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations.
Wilsmann-Theis D; Schnell LM; Ralser-Isselstein V; Bieber T; Schön MP; Hüffmeier U; Mössner R
J Dermatol; 2018 Jul; 45(7):850-854. PubMed ID: 29655177
[TBL] [Abstract][Full Text] [Related]
40. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
Leonardi C; Matheson R; Zachariae C; Cameron G; Li L; Edson-Heredia E; Braun D; Banerjee S
N Engl J Med; 2012 Mar; 366(13):1190-9. PubMed ID: 22455413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
